Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB57643 + Ruxolitinib in JAKi-naïve Myelofibrosis
NCT06619522Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of INCB-057643 in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Splenic Response Rate by Imaging at 24 weeks and Incidence of Treatment-Emergent Adverse Events. Planned start Sep 2024; status: withdrawn.
02
Drugs
INCB-057643
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06619522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619522.